Stock Price Quote

AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo
BSE1202.6538.8 (+3.33 %)
PREV CLOSE ( ) 1163.85
OPEN PRICE ( ) 1179.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 9054
TODAY'S LOW / HIGH ( )1150.25 1211.65
52 WK LOW / HIGH ( )581.5 1211.65
NSE1202.4037.35 (+3.21 %)
PREV CLOSE( ) 1165.05
OPEN PRICE ( ) 1165.05
BID PRICE (QTY) 1202.40 (1181)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 415670
TODAY'S LOW / HIGH( ) 1165.05 1212.00
52 WK LOW / HIGH ( )581.25 1190.2
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 26-12 1986
Management Info
- Chairman K Nithyananda Reddy - Managing Director
Registered Office

Address Plot No. 2,Maitrivihar ,Ameerpet,
Hyderabad,
Telangana-500038

Phone 040-23736370 / 23747340

Email info@aurobindo.com

Website www.aurobindo.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX

NEWS

13May Aurobindo Pharma trades in green on BSE
Aurobindo Pharma is currently trading at Rs. 1145.20, up by 16.55 points..
10May USFDA concludes inspection at Unit-VII
The United States Food and Drug Administration (US FDA) has completed th..
06May Aurobindo Pharma trades higher on the
Aurobindo Pharma is currently trading at Rs. 1168.50, up by 15.80 points..
03May USFDA concludes inspection at Unit-II
The United States Food and Drug Administration (USFDA) has concluded the..
02May Aurobindo Pharma informs about disclos
With reference to its letter dated February 5, 2024, informing about dis..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit6237.812304.1
Gross Profit 6872.2 16143.5
Operating Profit 8128.221646.8
Net Sales 26920.3127922.8

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  26643.70 (0.58%)
M.Cap ( in Cr)56616.00
Pfizer (BSE)
peergroup  4473.85 (1.59%)
M.Cap ( in Cr)20466.85
Glaxosmithkline Phar (BSE)
peergroup  2355.75 (2.80%)
M.Cap ( in Cr)39907.83
Concord Biotech (BSE)
peergroup  1494.85 (4.43%)
M.Cap ( in Cr)15638.55
Zydus Lifesciences (BSE)
peergroup  1104.45 (5.00%)
M.Cap ( in Cr)111133.51

Shareholding Pattern

NON-INSTITUTION 6.87%
PROMOTERS 51.83%
FI/BANKS/INSURANCE 5.03%
MUTUAL FUNDS/UTI 17.83%
GOVERNMENT 0%
FII 0%

About Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd. was incorporated in the year 1986. Its today's share price is 1202.65. Its current market capitalisation stands at Rs 70467.91 Cr. In the latest quarter, company has reported Gross Sales of Rs. 128850 Cr and Total Income of Rs.132260.4 Cr. The company's management includes Deepali Pant Joshi, Satakarni Makkapati, B Adi Reddy, Santanu Mukherjee, Girish Vanvari, Savita Mahajan, M Madan Mohan Reddy, PV Ramprasad Reddy, P Sarath Chandra Reddy, K Nithyananda Reddy.

It is listed on the BSE with a BSE Code of 524804 , NSE with an NSE Symbol of AUROPHARMA and ISIN of INE406A01037. It's Registered office is at Plot No. 2,Maitrivihar ,AmeerpetHyderabad-500038, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Associates LLP, Deloitte Haskins & Sells, K Nagaraju & Associates, SR Batliboi & Associates, SR Batliboi & Associates LLP, SR Batliboi & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.